Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Changes in clinical features of food-related anaphylaxis in children during 5 years - Motomura C, Okabe K, Matsuzaki H, Kawano T, Akamine Y, Yasunari D, Wakatsuki M, Taba N, Honjo S, Odajima H.
This study aimed to investigate recent changes in the clinical featu... (Source: SafetyLit)
Source: SafetyLit - May 23, 2022 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Needle-Free Epinephrine Options Are On The Horizon
Epinephrine is the only effective treatment for serious allergic reactions called anaphylaxis, yet people with prescriptions for the lifesaving medication often don't carry their auto-injectors, and many hesitate to use them. (Source: WebMD Health)
Source: WebMD Health - April 25, 2022 Category: Consumer Health News Source Type: news

Paracetamol: Drug can cause anaphylaxis in rare cases – serious symptoms to spot
PARACETAMOL is a drug common in most medicine cupboards in the UK. It is used for a number of minor problems and is effective at treating a lot of them. However, just like other drugs it can cause side effects. (Source: Daily Express - Health)
Source: Daily Express - Health - April 18, 2022 Category: Consumer Health News Source Type: news

Anaphylaxis Following Patch Testing Is Rare, Survey Finds Anaphylaxis Following Patch Testing Is Rare, Survey Finds
Anaphylactic reactions after patch testing occurred in fewer than 1 in 100,000 cases, and only in patients with a previous history of anaphylaxis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 1, 2022 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

Paraphenylenediamine (PPD) poisoning mistaken for an anaphylactic reaction - Elgassim M, Fadul KY, Abbas M, AlBakri F, Kamath R, Salem W.
Paraphenylenediamine (PPD) is commonly used in parts of Africa and Asia in combination with Lawsonia alba leaves (also widely known as henna) or as a substitute to dye the hair, palms, soles, or arms for wedding ceremonies or spiritual events. At the same ... (Source: SafetyLit)
Source: SafetyLit - March 31, 2022 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Anaphylaxis Risk With IV Iron Low, But Varies With Formulation Anaphylaxis Risk With IV Iron Low, But Varies With Formulation
"The rates of anaphylaxis were very low with all IV iron products but were three- to eightfold greater for iron dextran and ferumoxytol than for iron sucrose."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2022 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Risks for Anaphylaxis Compared Among IV Iron Products
Rates of anaphylaxis low for IV iron products, but risk for anaphylaxis increased with iron dextran and ferumoxytol compared with iron sucrose (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2022 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Allergy, Emergency Medicine, Nursing, Oncology, Pharmacy, Journal, Source Type: news

Risks for Anaphylaxis Compared Among IV Iron Products
TUESDAY, March 29, 2022 -- The rates of anaphylaxis are low for commonly used intravenous (IV) iron products, but the risk for anaphylaxis is increased for iron dextran and ferumoxytol compared with iron sucrose, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2022 Category: Pharmaceuticals Source Type: news

Pumping (IV) Iron Linked to Varying Anaphylaxis Risk for Older Adults
(MedPage Today) -- While the risk of anaphylaxis after administration of IV iron product was low among older adults, it was more common after certain iron products, researchers found. The highest adjusted incidence rates for anaphylaxis among... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 28, 2022 Category: Allergy & Immunology Source Type: news

New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news